- Home
- GBIO vs NTIP Comparison
GBIO vs NTIP Comparison
Compare GBIO & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- NTIP
- Stock Information
- Founded
- GBIO 2016
- NTIP 1990
- Country
- GBIO United States
- NTIP United States
- Employees
- GBIO N/A
- NTIP N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- GBIO Health Care
- NTIP Miscellaneous
- Exchange
- GBIO Nasdaq
- NTIP Nasdaq
- Market Cap
- GBIO 29.2M
- NTIP 28.6M
- IPO Year
- GBIO 2020
- NTIP 1998
- Fundamental
- Price
- GBIO $0.52
- NTIP $1.41
- Analyst Decision
- GBIO Strong Buy
- NTIP
- Analyst Count
- GBIO 4
- NTIP 0
- Target Price
- GBIO $7.33
- NTIP N/A
- AVG Volume (30 Days)
- GBIO 1.8M
- NTIP 29.5K
- Earning Date
- GBIO 08-06-2025
- NTIP 08-11-2025
- Dividend Yield
- GBIO N/A
- NTIP 7.25%
- EPS Growth
- GBIO N/A
- NTIP N/A
- EPS
- GBIO N/A
- NTIP N/A
- Revenue
- GBIO $24,556,000.00
- NTIP $250,000.00
- Revenue This Year
- GBIO N/A
- NTIP N/A
- Revenue Next Year
- GBIO N/A
- NTIP N/A
- P/E Ratio
- GBIO N/A
- NTIP N/A
- Revenue Growth
- GBIO 146.47
- NTIP N/A
- 52 Week Low
- GBIO $0.30
- NTIP $1.16
- 52 Week High
- GBIO $3.65
- NTIP $1.78
- Technical
- Relative Strength Index (RSI)
- GBIO 66.42
- NTIP 68.79
- Support Level
- GBIO $0.32
- NTIP $1.27
- Resistance Level
- GBIO $0.59
- NTIP $1.42
- Average True Range (ATR)
- GBIO 0.05
- NTIP 0.07
- MACD
- GBIO 0.02
- NTIP 0.02
- Stochastic Oscillator
- GBIO 76.34
- NTIP 96.15
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.